| Title |
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2013
|
| DOI | 10.2147/dddt.s41910 |
| Pubmed ID | |
| Authors |
Qian Ding, Jinbiao Zhan |
| Abstract |
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer characterized by early metastasis and high mortality. In recent years, monotherapy and combination therapy of amrubicin with cisplatin or carboplatin has been actively studied and shown promise for the treatment of extensive disease SCLC (ED-SCLC). In this article, we summarize clinical trials of both monotherapy and combination therapy with amrubicin conducted in Japan, the USA, and the European Union. The results suggest that the clinical outcome of amrubicin therapy may be associated with genetic variations in patients. Further study of combination regimens in patients of different ethnicities is warranted. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 29% |
| Student > Master | 3 | 21% |
| Other | 2 | 14% |
| Professor | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 1 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 29% |
| Agricultural and Biological Sciences | 2 | 14% |
| Immunology and Microbiology | 1 | 7% |
| Philosophy | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 1 | 7% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2013.
All research outputs
#16,722,190
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#1,011
of 2,268 outputs
Outputs of similar age
#128,082
of 210,078 outputs
Outputs of similar age from Drug Design, Development and Therapy
#19
of 43 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,078 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.